19.09.2012 - Mutabilis has received €4m funding from the European Union under its FP7 programme.
The project, submitted by the French specialist for infectious diseases, is called "HIVINNOV – generation of a new class of antiretrovirals targeting HIV-cellular cofactors interactions". Mutabilis, which is the coordinator of the €10.8m project, formed the consortium in July 2011 comprising eleven research institutions from across Europe. "The Commission was apparently very impressed with the major advances we have made with the compounds we are developing, as well as the quality of the consortium and the research projects proposed," said the scientific director of Mutabilis, Dr. Richard Benarous.
Mutabilis was founded in 2001 to develop new antibiotic treatments. The French company raised €11.8m in two financing rounds in 2002 and 2004. Mutabilis runs different collaborations, amongst others with German drug developer 4SC. In 2009 FAB Pharmaceuticals SAS acquired Mutabilis lead compound Fab-001, which is a marrow- spectrum antibiotic targeting the fatty acid biosynthesis in S. aureus. Since 2010, the company has been an affiliate of Pharma Omnium International.
The European Union's seventh framework program (FP7), which has been allotted a total budget of €50.5bn for the 2007-2013 period, brings together all the EU's research initiatives under one roof and plays an important role in achieving its growth, competitiveness and employment targets. A budget of €6.05 billion has been assigned to cooperation in human health.
25.11.2014 The European biotech IPO slump has finally come to an end. A brand new industry report shows that compared to previous years, the number of biotech IPOs more than doubled in 2014, with London and Paris exchanges leading the pack.
19.11.2014 It’s not every day that a company is pushed into the top ten of its sector, but that day has come for Actavis. Christmas came early for the new pharma giant after completing a US$66bn (€53bn) takeover battle for the Botox manufacturer Allergan.
18.11.2014 Merck KGaA and US rival Pfizer have signed a immuno-oncology alliance worth billions: Merck will share the development and commercialisation of its cancer antibody with its US partner – for €2.3bn.
14.11.2014 Cosily coinciding with World Diabetes Day on 14th November, French biopharma Les Laboratories Servier has struck a US$1bn deal with US pharma Intarcia Therapeutics for the exclusive rights to Intarcia’s unprecedented therapy for type 2 diabetes.
12.11.2014 Glitz and glamour are not words often used to describe science and mathematics. But once a year, celebrities from the science and showbiz world come together at the Breakthough Prizes, a glitzy television bash that honours scientists for their achievements. French life scientist Emmanuelle Charpentier was among this year’s winners.
04.11.2014 Galecto Biotech has entered an agreement with Bristol-Myers Squibb for the acquisition of the company and its lead drug, providing the Swedish company with the potential of reaching over US$400m.